ClinicalTrials.gg
CompletedNCT02560974Updated Nov 2, 2016

A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer

A Phase 3 interventional study of Capecitabine and Oxaliplatin in Gastric Cancer, sponsored by Hoffmann-La Roche. Completed at 36 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,035
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 100 studies testing capecitabine in Stomach Neoplasms — 9 open to participants now, 13 under way, 5 of them phase 3. Capecitabine · Stomach Neoplasms.

Enrollment
Largest of 97
1,035 · median 50
Started
2006
with 7 others
Phase 3
17 of 100
4 open now
Registered
77th of 100
by date
Lead sponsor
5 of 100
Hoffmann-La Roche

Among the 100 studies testing capecitabine in Stomach Neoplasms, this one has the largest enrollment of the 97 interventional ones that give a count, is one of 8 that started in 2006, is one of 17 in phase 3, and was the 77th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

9 of the 100 studies testing capecitabine in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing capecitabine in Stomach Neoplasms, or all of them as a file.
02

Study summary

This study will compare capecitabine/oxaliplatin as adjuvant chemotherapy versus observation alone in chemotherapy-naive participants who have undergone potentially curative resection for gastric cancer. Participants will be randomized to either the chemotherapy arm or the observation arm. Capecitabine will be administered orally, 1000 milligrams per meter-squared (mg/m\^2) twice daily (BID) on Days 1 to 15 of a 3-week cycle, for 8 cycles, and oxaliplatin will be administered as an intravenous (IV) infusion, 130 mg/m\^2 every 3 weeks for 8 cycles. The anticipated time on study treatment in 6 months and the target sample size is 1024 individuals.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants greater than or equal to (>=) 18 years of age
  • Gastric adenocarcinoma, Stage II, IIIa or IIIb
  • Potentially curative resection of tumor within 6 weeks prior to randomization
  • Previously untreated with chemotherapy or radiotherapy

Exclusion criteria

Exclusion Criteria:

  • Serious concomitant medical illnesses that would limit to less than (\<) 5 years
  • Sexually active males and females (of ) unwilling to practice during the study
  • Any evidence of disease (including presence of tumor cells in the ascites)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,035 participants (actual)

Study arms

  • Experimental
    Capecitabine + Oxaliplatin

    Patients will receive oral capecitabine (1000 mg/m\^2 BID on Days 1 to 15 ) plus IV oxaliplatin (130 mg/m\^2 on Day 1) during each 3-week cycle for up to 8 cycles (6 months).

    Drug: Capecitabine · Drug: Oxaliplatin

  • No intervention
    Observation

    Participants will not receive any treatment but will be seen regularly by a physician.

Interventions

  • Capecitabine will be administered orally at 1000 mg/m\^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.

    Also known as: Xeloda

  • Oxaliplatin will be administered as an IV infusion, 130 mg/m\^2 on Day 1 of each 3-week cycle for 8 cycles.

06

What researchers measure

Primary outcomes

  1. Disease-free survival rate

    Time frame: 3 years

Secondary outcomes

  1. Overall survival

    Time frame: 5 years

  2. Incidence of adverse events

    Time frame: 5 years

07

Study locations

36 sites
  • Beijing, 100044, China
  • Beijing, 100142, China
  • Fujian, 350001, China
  • Guangzhou, 510060, China
  • Guangzhou, 510080, China
  • Shanghai, 200025, China
  • Shanghai, 200032, China
  • Shenyang, 110001, China
  • Tianjin, 300060, China
  • Bundang City, 463-802, Korea, Republic of
  • Busan, 49267, Korea, Republic of
  • Daegu, 700-712, Korea, Republic of
  • Daegu, 702-210, Korea, Republic of
  • Daegu, Korea, Republic of
  • Gyeonggi-do, 10408, Korea, Republic of
  • Gyeonggi-do, 443-380, Korea, Republic of
  • Incheon, 405-760, Korea, Republic of
  • Jeollabuk-do, 561-712, Korea, Republic of
  • Jeollanam-do, 58128, Korea, Republic of
  • Seoul, 03080, Korea, Republic of
  • Seoul, 120-752, Korea, Republic of
  • Seoul, 130-872, Korea, Republic of
  • Seoul, 134-791, Korea, Republic of
  • Seoul, 135-720, Korea, Republic of
  • Seoul, 139-709, Korea, Republic of
  • Seoul, 140-743, Korea, Republic of
  • Seoul, 152-703, Korea, Republic of
  • Seoul, 158-710, Korea, Republic of
  • Seoul, Korea, Republic of
  • Suwon, Korea, Republic of
  • Changhua, 500, Taiwan
  • Tainan, 704, Taiwan
  • Taipei, 00112, Taiwan
  • Taipei, 104, Taiwan
  • Taipei, Taiwan
  • Taoyuan, 333, Taiwan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2015
First posted
Sep 25, 2015
Start
Jun 2006
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02560974
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 25, 2015
Start date
Jun 2006
Primary completion
Nov 2012
Completion
Nov 2012
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Oxaliplatin

Start the discussion